The class I, II and IV HDAC inhibitor Pracinostat, corrects pre-mRNA splicing of the BIM pro-apoptotic protein to overcome BIM deletion polymorphism-induced TKI resistance observed in certain CML cases [53]. This evidence concerns the gene HDAC9 and chronic myelogenous leukemia, BCR-ABL1 positive.